VERA RSI Chart
Last 7 days
0.5%
Last 30 days
3.8%
Last 90 days
-9.7%
Trailing 12 Months
461.1%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 10, 2024 | young joseph r | sold | -228,560 | 40.00 | -5,714 | svp, finance, chief acct offcr |
Apr 03, 2024 | grant sean | acquired | 1,484,440 | 14.87 | 99,828 | chief financial officer |
Apr 03, 2024 | grant sean | sold | -3,954,520 | 39.6133 | -99,828 | chief financial officer |
Apr 03, 2024 | grant sean | sold | -111,016 | 39.4233 | -2,816 | chief financial officer |
Apr 03, 2024 | grant sean | sold | -63,865 | 39.4232 | -1,620 | chief financial officer |
Apr 03, 2024 | grant sean | sold | -13,206 | 39.4234 | -335 | chief financial officer |
Apr 03, 2024 | grant sean | sold | -33,785 | 39.4234 | -857 | chief financial officer |
Apr 03, 2024 | grant sean | sold | -513,331 | 39.4233 | -13,021 | chief financial officer |
Mar 25, 2024 | katabi maha | sold | -13,770,000 | 40.5 | -340,000 | - |
Mar 22, 2024 | katabi maha | sold | -16,748,900 | 40.51 | -413,450 | - |
Which funds bought or sold VERA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 18.66 | 975,892 | 1,395,320 | -% |
May 16, 2024 | COMERICA BANK | new | - | 2,070 | 2,070 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 2,575,940 | 2,575,940 | -% |
May 15, 2024 | NOMURA HOLDINGS INC | new | - | 599,584 | 599,584 | -% |
May 15, 2024 | Voya Investment Management LLC | added | 642 | 4,193,650 | 4,405,310 | -% |
May 15, 2024 | Mariner, LLC | new | - | 296,795 | 296,795 | -% |
May 15, 2024 | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | reduced | -74.23 | -456,583 | 1,188,650 | 0.09% |
May 15, 2024 | ORBIMED ADVISORS LLC | reduced | -55.48 | 5,794,990 | 29,143,600 | 0.53% |
May 15, 2024 | J. Goldman & Co LP | new | - | 1,301,400 | 1,301,400 | 0.04% |
May 15, 2024 | WEXFORD CAPITAL LP | new | - | 262,558 | 262,558 | 0.05% |
Unveiling Vera Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Vera Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Vera Therapeutics, Inc. News
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | 138.9% | 419 | 176 | 176 | 195 | 210 | 131 | 131 | 149 | 165 | 84.00 | 91.00 | 98.00 | 52.00 | 55.00 | 5.00 |
Current Assets | 142.0% | 416 | 172 | 172 | 191 | 204 | 126 | 125 | 142 | 158 | 83.00 | 90.00 | 96.00 | 52.00 | 54.00 | 4.00 |
Cash Equivalents | 51.3% | 69.00 | 46.00 | 27.00 | 34.00 | 137 | 43.00 | 31.00 | 51.00 | 112 | 80.00 | 86.00 | 92.00 | 50.00 | 54.00 | 4.00 |
Net PPE | -12.0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | 1.00 |
Liabilities | -10.9% | 66.00 | 74.00 | 52.00 | 55.00 | 52.00 | 55.00 | 26.00 | 27.00 | 31.00 | 14.00 | 6.00 | 5.00 | 6.00 | 4.00 | 2.00 |
Current Liabilities | -34.8% | 15.00 | 22.00 | 25.00 | 27.00 | 24.00 | 26.00 | 16.00 | 17.00 | 20.00 | 8.00 | 4.00 | 4.00 | 4.00 | 2.00 | 1.00 |
Long Term Debt | 0.4% | 50.00 | 50.00 | 25.00 | 25.00 | 25.00 | 25.00 | 5.00 | 5.00 | 5.00 | 5.00 | - | - | - | - | - |
Shareholder's Equity | 247.7% | 354 | 102 | 124 | 141 | 158 | 77.00 | 106 | 122 | 134 | 70.00 | 85.00 | 92.00 | - | - | - |
Retained Earnings | -9.2% | -337 | -309 | -283 | -263 | -243 | -213 | -180 | -155 | -141 | -124 | -107 | -99.60 | -96.16 | -91.45 | -38.03 |
Additional Paid-In Capital | 68.4% | 691 | 410 | 407 | 404 | 401 | 290 | 287 | 278 | 276 | 194 | 193 | 192 | 3.00 | 2.00 | 1.00 |
Shares Outstanding | 19.4% | 51.00 | 43.00 | 42.00 | 41.00 | 38.00 | 27.00 | 26.00 | 26.00 | 24.00 | 13.00 | 21.00 | 10.00 | - | 0.00 | 0.00 |
Float | - | - | - | - | 449 | - | - | - | 163 | - | - | - | 94.00 | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Cashflow From Operations | -34.5% | -33,830 | -25,144 | -22,973 | -17,772 | -26,292 | -21,162 | -18,420 | -19,033 | -8,981 | -6,438 | -5,484 | -7,665 | -4,121 | -27,382 | -2,447 | -2,675 | -2,305 | - |
Share Based Compensation | 28.0% | 4,124 | 3,221 | 2,923 | 2,682 | 2,667 | 2,748 | 2,452 | 2,025 | 1,662 | 962 | 933 | 713 | 404 | 143 | 116 | 11.00 | 61.00 | - |
Cashflow From Investing | -1281.8% | -219,286 | 18,556 | 16,228 | -86,449 | 12,234 | 13,437 | -2,440 | -42,094 | -39,455 | -5,000 | - | 796 | - | 57.00 | - | -47.00 | -52.00 | - |
Cashflow From Financing | 1013.8% | 276,540 | 24,828 | 297 | 432 | 107,984 | 20,709 | 908 | 48.00 | 80,268 | 4,921 | - | 48,989 | -28.00 | 79,801 | -94.00 | 616 | 4,967 | - |
Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 23,200 | $ 25,108 |
General and administrative | 7,912 | 6,150 |
Total operating expenses | 31,112 | 31,258 |
Loss from operations | (31,112) | (31,258) |
Other income (expense): | ||
Interest income | 4,186 | 1,623 |
Interest expense | (1,906) | (874) |
Other income | 453 | 441 |
Change in fair value of non-marketable equity securities | (4) | (1) |
Total other income | 2,729 | 1,189 |
Net loss | (28,383) | (30,069) |
Other comprehensive income (loss): | ||
Change in unrealized (loss) gain on marketable securities | (424) | 220 |
Comprehensive loss | $ (28,807) | $ (29,849) |
Net loss per share attributable to common stockholders, basic | $ (0.56) | $ (0.8) |
Net loss per share attributable to common stockholders, diluted | $ (0.56) | $ (0.8) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | 50,971,933 | 37,667,566 |
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted | 50,971,933 | 37,667,566 |
Condensed Balance Sheet - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 69,105 | $ 45,681 |
Marketable securities | 334,559 | 115,035 |
Prepaid expenses and other assets, current | 12,706 | 11,307 |
Total current assets | 416,370 | 172,023 |
Property and equipment, net | 81 | 92 |
Operating lease right-of-use assets | 2,432 | 2,949 |
Prepaid expenses and other assets, noncurrent | 473 | 482 |
Total assets | 419,356 | 175,546 |
Current liabilities: | ||
Accounts payable | 5,209 | 11,118 |
Operating lease liabilities | 2,275 | 2,436 |
Accrued expenses and other liabilities, current | 7,059 | 8,749 |
Total current liabilities | 14,543 | 22,303 |
Long-term debt | 50,066 | 49,877 |
Operating lease liabilities, noncurrent | 919 | 1,395 |
Accrued expenses and other liabilities, noncurrent | 286 | 286 |
Total liabilities | 65,814 | 73,861 |
Stockholders' equity | ||
Preferred stock, $0.001 par value; 10,000,000 authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Class A common stock, $0.001 par value; 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 54,457,371 and 44,452,161 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 54 | 44 |
Additional paid-in capital | 691,146 | 410,492 |
Accumulated other comprehensive income (loss) | (173) | 251 |
Accumulated deficit | (337,485) | (309,102) |
Total stockholders' equity | 353,542 | 101,685 |
Total liabilities and stockholders' equity | $ 419,356 | $ 175,546 |